68-1

64/98

62M, Mogushi K, Hlaing MT, Sasaki R, Saeki H, Okazaki M, Sonoue H, Arakawa A, Saito M: Estrogen receptor-positive ductal carcinoma in situ frequently overexpresses HER2 protein without gene amplification. Am J Surg Pathol, 2019; 43: 1221-8.) Saeki H, Hlaing MT, Horimoto Y, Kajino K, Ohtsuji N, Fujino K, Terao Y, Hino O: Useful‑ness of immunohistochemistry for mismatch repair protein and microsatellite instability examination in adenocarcinoma and back‑ground endometrium of sporadic endometrial cancer cases. J Obstet Gynaecol Res, 2019; 45: 2037-42.) Miyoshi Y, Shien T, Ogiya A, Ishida N, Yamazaki K, Horii R, Horimoto Y, Masuda N, Yasojima H, Inao T, Osako T, Takahashi M, Tomioka N, Wanifuchi-Endo Y, Hosoda M, Doihara H, Yamashita H: Associations in tumor infiltrating lymphocytes between clin‑icopathological factors and clinical outcomes in estrogen receptor‑positive/human epidermal growth factor receptor type 2 negative breast cancer. Oncol Lett, 2019; 17: 2177-86. 8 9 10) Ito M, Horimoto Y, Tokuda E, Murakami F, Uomori T, Himuro T, Nakai K, Orihata G, Iijima K, Saito M: Impact of circulating tumour cells on survival of eribulin-treated patients with metastatic breast cancer. Med Oncol, 2019; 36: 89. 11) Uomori T, Horimoto Y, Arakawa A, Iijima K, Saito M: Breast Cancer in Lean Postmeno‑pausal Women Might Have Specific Patho‑logical Features. In Vivo, 2019; 33: 483-7. 12) Nomura H, Sekine M, Yokoyama S, Arai M, Enomoto T, Takeshima N, Nakamura S: Clin‑ical background and outcomes of risk-re‑ducing salpingo-oophorectomy for heredi‑tary breast and ovarian cancers in Japan. Int J Clin Oncol, 2019; 24: 1105-10. 13) Yoshida R, Watanabe C, Yokoyama S, Inuzuka M, Yotsumoto J, Arai M, Nakamura S: Regis‑tration Committee of the Japanese HBOC Consortium. Analysis of clinical characteris‑tics of breast cancer patients with the Japa‑nese founder mutation BRCA1 L63X. Onco‑target, 2019; 10: 3276-84. 14) Shimada S, Yoshida R, Nakashima E, Kitagawa D, Gomi N, Horii R, Takeuchi S, Ashihara Y, Kita M, Akiyama F, Ohno S, Saito M, Arai M: Five screening-detected breast cancer cases in initially disease-free BRCA1 or BRCA2 mutation carriers. Breast Cancer, 2019; 26: 846-51. 15) Nakano K, Kawachi H, Chino S, Kita M, Arai M, Ide D, Saito S, Yoshimizu S, Yusuke Hori‑uchi Y, Ishiyama A, Yoshio T, Hirasawa T, Tsuchida T, Fujisaki J: Phenotypic variations of gastric neoplasms in familial adenomatous polyposis are associated with the endoscopic status of atrophic gastritis. Dig Endosc 2019 (doi: 10.1111/den.13512.) 16) Kanemaru K, Noguchi E, Tahara-Hanaoka S, Mizuno S, Tateno H, Denda-Nagai K, Irimura T, Matsuda H, Sugiyama F, Takahashi S, Shibuya K, Shibuya A: Clec10a regulates mite-induced dermatitis. Sci Immunol, 2019; 4: eaax6908. 17) Yoshimura Y, Denda-Nagai K, Takahashi Y, Nagashima I, Shimizu H, Kishimoto T, Noji M, Shichino S, Chiba Y, Irimura T: Products of chemoenzymatic synthesis representing MUC1 tandem repeat unit with T-, ST- or STn-antigen revealed distinct specificities of anti-MUC1 antibodies. Sci Rep, 2019; 9: 16641. 18) Higashi N, Maeda R, Sesoko N, Isono M, Ishi‑kawa S, Tani Y, Takahashi K, Oku T, Higashi K, Onishi S, Nakajima M, Irimura T: Chon‑droitin sulfate E blocks enzymatic action of heparanase and heparanase-induced cellular responses. Biochem Biophys Res Commun, 2019; 520: 152-8. 19) Yoshimoto T, Matsubara D, Soda M, Ueno T, Amano Y, Kihara A, Sakatani T, Nakano T, Shibano T, Endo S, Hagiwara K, Fukayama M, Denda-Nagai K, Irimura T, Mano H, Niki T: Mucin 21 is a key molecule involved in the incohesive growth pattern in lung adenocar‑cinoma. Cancer Sci, 2019; 110: 3006-11. 20) Matsumura M, Okudera K, Nakashima Y, Mitsui H, Denda-Nagai K, Suzuki T, Arai H, Umeda S, Tateishi Y, Koike C, Kataoka T, Irimura T, Ohashi K: Specific expression of MUC21 in micropapillary elements of lung adenocarcinomas- the progression of EGFR-mutated lung adeno‑carcinomas. PLoS One, 2019; 14: e0215237. 21) Fujiwara Y, Mukai H, Saeki T, Ro J, Lin YC, Implications for